EP1581633A4 - Clonage de genes de cytochrome p450 derives de plantes nicotiana - Google Patents

Clonage de genes de cytochrome p450 derives de plantes nicotiana

Info

Publication number
EP1581633A4
EP1581633A4 EP03809043A EP03809043A EP1581633A4 EP 1581633 A4 EP1581633 A4 EP 1581633A4 EP 03809043 A EP03809043 A EP 03809043A EP 03809043 A EP03809043 A EP 03809043A EP 1581633 A4 EP1581633 A4 EP 1581633A4
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
nicotiana
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03809043A
Other languages
German (de)
English (en)
Other versions
EP1581633A2 (fr
Inventor
Dongmei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Smokeless Tobacco Co LLC
Original Assignee
US Smokeless Tobacco Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Smokeless Tobacco Co LLC filed Critical US Smokeless Tobacco Co LLC
Priority to EP10000366A priority Critical patent/EP2204444A1/fr
Priority to EP11000745A priority patent/EP2336305A3/fr
Publication of EP1581633A2 publication Critical patent/EP1581633A2/fr
Publication of EP1581633A4 publication Critical patent/EP1581633A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)

Definitions

  • the present invention relates to nucleic acid sequences encoding cytochrome p450 enzymes (hereinafter referred to as p450 and p450 enzymes) in Nicotiana plants and methods for using those nucleic acid sequences to alter plant phenotypes.
  • p450 and p450 enzymes cytochrome p450 enzymes
  • Cytochrome p450s catalyze enzymatic reactions for a diverse range of chemically dissimilar substrates that include the oxidative, peroxidative and reductive metabolism of endogenous and xenobiotic substrates.
  • p450s participate in biochemical pathways that include the synthesis of plant products such as phenylpropanoids, alkaloids, terpenoids, lipids, cyanogenic glycosides, and glucosinolates (Chappel, Annu. Rev. Plant Physiol. Plant Mol. Biol. 198, 49:311-343) .
  • Cytochrome p450s also known as p450 heme-thiolate proteins, usually act as terminal oxidases in multi- component electron transfer chains, called p450- containing monooxygenase systems. Specific reactions catalyzed include demethylation, hydroxylation, epoxidation, N-oxidation, sulfooxidation, N-, S-, and O- dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups.
  • Nicotiana plant p450 enzymes have been implicated in effecting a variety of plant metabolites such as phenylpropanoids, alkaloids, terpenoids, lipids, cyanogenic glycosides, glucosinolates and a host of other chemical entities.
  • plant metabolites such as phenylpropanoids, alkaloids, terpenoids, lipids, cyanogenic glycosides, glucosinolates and a host of other chemical entities.
  • some p450 enzymes can impact the composition of plant metabolites in plants. For example, it has been long desired to improve the flavor and aroma of certain plants by altering its profile of selected fatty acids through breeding; however very little is known about mechanisms involved in controlling the levels of these leaf constituents.
  • the down regulation of p450 enzymes associated with the modification of fatty acids may facilitate accumulation of desired fatty acids that provide more preferred leaf phenotypic qualities.
  • p450 enzymes The function of p450 enzymes and their broadening roles in plant constituents is still being discovered. For instance, a special class of p450 enzymes was found to catalyze the breakdown of fatty acid into volatile C6- and C9-aldehydes and -alcohols that are major contributors of "fresh green" odor of -fruits and vegetables.
  • the level of other novel targeted p450s may be altered to enhance the qualities of leaf constituents by modifying lipid composition and related break down metabolites in Nicotiana leaf. Several of these constituents in leaf are affected by senescence that stimulates the maturation of leaf quality properties. Still other reports have shown that p450s enzymes are play S functional role in altering fatty acids that are involved in plant-pathogen interactions and disease resistance.
  • p450 enzymes have been suggested. to be involved in alkaloid biosynthesis.
  • Nornicotine is a minor alkaloid found in Nicotiana tabaceum. It has been postulated that it is produced by the p450 mediated demethylation of nicotine followed by acylation and nitrosation at the N position thereby producing a series of N-acylnonicotines and N-nitrosonornicotines .
  • N- demethylation catalyzed by a putative p450 demethylase, is thought to be a primary source of nornicotine biosyntheses in Nicotiana . While the enzyme is believed to be microsomal, thus far a nicotine demethylase enzyme has not been successfully purified, nor have the genes involved been isolated.
  • the activity of p450 ⁇ enzymes is genetically controlled and also strongly influenced by environment factors. For example, the demethylation of nicotine in Nicotiana is thought to increase substantially when the plants reach a mature stage. Furthermore, it is hypothesized yet not proven that the demethylase gene contains a transposable element that can inhibit translation of RNA when present.
  • the present invention is directed to plant p450 enzymes.
  • the present invention is further directed to plant p450 enzymes from Nicotiana .
  • the present invention is also directed to p450 enzymes in plants whose expression is induced by ethylene and/or plant senescence.
  • the present invention is yet further directed to nucleic acid sequences in plants having enzymatic activities, for example, being categorized as oxygenase, demethylase and the like, or other and the use of those sequences to reduce or silence the expression or over-expression of these enzymes.
  • the invention also relates to p450 enzymes found in plants containing higher nornicotine levels than plants exhibiting lower nornicotine levels.
  • the invention is directed to nucleic acid sequences as set forth in SEQ. ID. Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195
  • those fragments containing greater than 75% identity in nucleic acid sequence were placed into groups dependent upon their identity in a region corresponding to the first nucleic acid following the cytochrome p450 motif GXRXCX(G/A) to the stop codon.
  • the representative nucleic acid groups and respective species are shown in Table I.
  • the invention is directed to amino acid sequences as set forth in SEQ. ID. Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188 , 190, 192, 194 , 196
  • those fragments containing greater than 71% identity in amino acid sequence were placed into groups dependent upon their identity to each other in a region corresponding to the first amino acid following the cytochrome p450 motif GXRXCX(G/A) to the stop codon.
  • the representative amino acid groups and respective species are shown in Table II.
  • the invention is directed to amino acid sequences of full length genes as set forth in SEQ. ID. Nos. 150, 152, 154, 156, 158, 160, 162, 164 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296 and 298.
  • the invention is directed to amino acid sequences of the fragments set forth in SEQ. ID. Nos. 299-357.
  • those fragments containing 90% or greater identity in amino acid sequence were placed into groups dependent upon their identity to each other in a region corresponding to the first cytochrome p450 domain, UXXRXXZ, to the third cytochrome domain, GXRXO, where U is E or K, X is any amino acid and Z is R, T, S or M.
  • the representative amino acid groups respective species shown in Table IV.
  • the reduction or elimination or over-expression of p450 enzymes in Nicotiana plants may be accomplished transiently using RNA viral systems .
  • Resulting transformed or infected plants are assessed for phenotypic changes including, but not limited to, analysis of endogenous p450 RNA transcripts, p450 expressed peptides, and concentrations of plant metabolites using techniques commonly available to one having ordinary skill in the art.
  • the present invention is also directed to generation of trangenic Nicotiana lines that have altered p450 enzyme activity levels.
  • these transgenic lines include nucleic acid sequences that are effective for reducing or silencing or increasing the expression of certain enzyme thus resulting in phenotypic effects within Nicotiana.
  • nucleic acid sequences include SEQ. ID. Nos.
  • plant cultivars including nucleic acids of the present invention in a down regulation capacity using either full length genes or fragments thereof or in an over-expression capacity using full length genes will have altered metabolite profiles relative to control plants.
  • plant cultivars including nucleic acid of the present invention using either full length genes or fragments thereof in modifying the biosynthesis or breakdown of metabolites derived from the plant or external to the plants will have use in tolerating certain exogenous chemicals or plant pests.
  • nucleic acid sequences include SEQ ID. Nos.
  • the present invention is directed to the screening of plants, more preferably Nicotiana, that contain genes that have substantial nucleic acid identity to the taught nucleic acid sequence.
  • the use of the invention would be advantageous to identify and select plants that contain a nucleic acid sequence with exact or substantial identity where such plants are part of a breeding program for traditional or transgenic varieties, a mutagenesis program, or naturally occurring diverse plant populations.
  • the screening of ants for substantial nucleic acid identity may be accomplished by evaluating plant nucleic acid materials using a nucleic acid probe in conjunction with nucleic acid detection protocols including, but not limited to, nucleic acid hybridization and PCR analysis.
  • the nucleic acid probe may consist of the taught nucleic acid sequence or fragment thereof corresponding to SEQ ID 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195,
  • the present invention is directed to the identification of plant genes, more preferably Nicotiana, that share substantial amino acid identity corresponding to the taught nucleic acid sequence.
  • the identification of plant genes including both cDNA and genomic clones, those cDNAs and genomic clones, more preferably from Nicotiana may be accomplished by screening plant cDNA libraries using a nucleic acid probe in conjunction with nucleic acid detection protocols including, but not limited to, nucleic acid hybridization and PCR analysis.
  • the nucleic acid probe may be comprised of nucleic acid sequence or ⁇ fragment thereof corresponding to SEQ ID 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 143, 145 and 147.
  • cDNA expression libraries that express peptides may be screened using antibodies directed to part or all of the taught amino acid sequence.
  • amino acid sequences include SEQ ID 2, 4, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 144, 146, 148.
  • the present invention is also directed to generation of transgenic Nicotiana lines that have over-expression of p450 enzyme activity levels.
  • these transgenic lines include all nucleic acid sequences encoding the amino acid sequences of full length genes that are effective for increasing the expression of certain enzyme thus resulting in phenotypic effects within Nicotiana.
  • amino acid sequences include SEQ. ID. 150, 152, 154, 156, 158, 160, 162, 164, 166, 168,
  • Figure 1 shows nucleic acid SEQ. ID. No.: 1 and amino acid SEQ. ID. No. :2.
  • Figure 2 shows nucleic acid SEQ. ID. No. : 3 and amino acid SEQ. ID. No . : 4.
  • Figure 3 shows nucleic acid SEQ. ID. No.: 5 and amino acid SEQ. ID. No . : 6.
  • Figure 4 shows nucleic acid SEQ. ID. No.; 7 and amino acid SEQ. ID. No . : 8.
  • Figure 5 shows nucleic acid SEQ. ID. No.: 9 and amino acid SEQ. ID. No. :10.
  • Figure 6 shows nucleic acid SEQ. ID. No . : 11 and amino acid SEQ. ID. No.: 12.
  • Figure 7 shows nucleic acid SEQ. ID. No. : 13 and amino acid SEQ. ID. No.: 14.
  • Figure 8 shows nucleic acid SEQ. ID. No. : 15 and amino acid SEQ. ID. No.: 16.
  • Figure 9 shows nucleic acid SEQ. ID. No. : 17 and amino acid SEQ. ID. No.: 18.
  • Figure 10 shows nucleic acid SEQ. ID. No.: 19 and amino acid SEQ. ID. No.:20.
  • Figure 11 shows nucleic acid SEQ. ID. No . : 21 and amino acid SEQ. ID. No.: 22.
  • Figure 12 shows nucleic acid SEQ. ID. No.: 23 and amino acid SEQ. ID. No.: 24.
  • Figure 13 shows nucleic acid SEQ. ID. No.:25 and amino acid SEQ. ID. No.: 26.
  • Figure 14 shows nucleic acid SEQ. ID. No.:27 and amino acid SEQ. ID. No.: 28.
  • Figure 15 shows nucleic acid SEQ. ID. No.:29 and amino acid SEQ. ID. No.: 30.
  • Figure 16 shows nucleic acid SEQ. ID. No.:31 and amino acid SEQ. ID. No.: 32.
  • Figure 17 shows nucleic acid SEQ. ID. No.:33 and amino acid SEQ. ID. No.:34.
  • Figure 18 shows nucleic acid SEQ. ID. No.:35 and amino acid SEQ. ID. No.: 36.
  • Figure 19 shows nucleic acid SEQ. ID. No.:37 and amino acid SEQ. ID. No.: 38.
  • Figure 20 shows nucleic acid SEQ. ID. No.:39 and amino acid SEQ. ID. No.: 40.
  • Figure 21 shows nucleic acid SEQ. ID. No.:41 and amino acid SEQ. ID. No.: 42.
  • Figure 22 shows nucleic acid SEQ. ID. No.:43 and amino acid SEQ. ID. No.: 44.
  • Figure 23 shows nucleic acid SEQ. ID. No.:45 and amino acid SEQ. ID. No.: 46.
  • Figure 24 shows nucleic acid SEQ. ID. No.:47 and amino acid SEQ. ID. No.: 48.
  • Figure 25 shows nucleic acid SEQ. ID. No.:49 and amino acid SEQ. ID. No.: 50.
  • Figure 26 shows nucleic acid SEQ. ID. No.: 51 and amino acid SEQ. ID. No.: 52.
  • Figure 27 shows nucleic acid SEQ. ID. No.:53 and amino acid SEQ. ID. No.: 54.
  • Figure 28 shows nucleic acid SEQ. ID. No.:55 and amino acid SEQ. ID. No.: 56.
  • Figure 29 shows nucleic acid SEQ. ID. No.:57 and amino acid SEQ. ID. No.: 58.
  • Figure 30 shows nucleic acid SEQ. ID. No.:59 and amino acid SEQ. ID. No.: 60.
  • Figure ' 31 shows nucleic acid SEQ. ID. No.: 61 and amino acid SEQ. ID. No.: 62.
  • Figure 32 shows nucleic acid SEQ. ID. No . : 63 and amino acid SEQ. ID. No.: 64.
  • Figure 33 shows nucleic acid SEQ. ID. No.: 65 and amino acid SEQ. ID. No.: 66.
  • Figure 34 shows nucleic acid SEQ. ID. No . : 67 and amino acid SEQ. ID. No.: 68.
  • Figure 35 shows nucleic acid SEQ. ID. No.: 69 and amino acid SEQ. ID. No.: 70.
  • Figure 36 shows nucleic acid SEQ. ID. No.:71 and amino acid SEQ. ID. No.: 72.
  • Figure 37 shows nucleic acid SEQ. ID. No.:73 and amino acid SEQ. ID. No.: 74.
  • Figure 38 shows nucleic acid SEQ. ID. No.:75 and amino acid SEQ. ID. No.: 76.
  • Figure 39 shows nucleic acid SEQ. ID. No.:77 and amino acid SEQ. ID. No.: 78.
  • Figure 40 shows nucleic acid SEQ. ID. No.:79 and amino acid SEQ. ID. No.: 80.
  • Figure 41 shows nucleic acid SEQ. ID. No.:81 and amino acid SEQ. ID. No.: 82.
  • Figure 42 shows nucleic acid SEQ. ID. No.: 83 and amino acid SEQ. ID. No.: 84.
  • Figure 43 shows nucleic acid SEQ. ID. No.:85 and amino acid SEQ. ID. No.: 86.
  • Figure 44 shows nucleic acid SEQ. ID. No.:87 and amino acid SEQ. ID. No.: 88.
  • Figure 45 shows nucleic acid SEQ. ID. No.:89 and amino acid SEQ. ID. No.: 90.
  • Figure 46 shows nucleic acid SEQ. ID. No.:91 and amino acid SEQ. ID. No.: 92.
  • Figure 48 shows nucleic acid SEQ. ID. No.: 95 and amino acid SEQ. ID. No.: 96.
  • Figure 49 shows nucleic acid SEQ. ID. No.: 97 and amino acid SEQ. ID. No.: 98.
  • Figure 50 shows nucleic acid SEQ. ID. No.:99.and amino acid SEQ. ID. No.: 100.
  • Figure 51 shows nucleic acid SEQ. ID. No.: 101 and amino acid SEQ. ID. No.: 102.
  • Figure 52 shows nucleic acid SEQ. ID. No.:103 and amino acid SEQ. ID. No.: 104.
  • Figure 53 shows nucleic acid SEQ. ID. No.: 105 and amino acid SEQ. ID. No.: 106.
  • Figure 54 shows nucleic acid SEQ. ID. No.: 107 and amino acid SEQ. ID. No.: 108.
  • Figure 55 shows nucleic acid SEQ. ID. No.: 109 and amino acid SEQ. ID. No.: 110.
  • Figure 56 shows nucleic acid SEQ. ID. No.: Ill and amino acid SEQ. ID. No.: 112.
  • Figure 57 shows nucleic acid SEQ. ID. No.: 113 and amino acid SEQ. ID. No.: 114.
  • Figure 58 shows nucleic acid SEQ. ID. No.:115 and amino acid SEQ. ID. No.: 116.
  • Figure 59 shows nucleic acid SEQ. ID. No.:117 and amino acid SEQ. ID. No.:118.
  • Figure 60 shows nucleic acid SEQ. ID. No.:119 and amino acid SEQ. ID. No.: 120.
  • Figure 61 shows nucleic acid SEQ. ID. No.:121 and amino acid SEQ. ID. No.: 122.
  • Figure 62 shows nucleic acid SEQ. ID. No.:123 and amino acid SEQ. ID. No.: 124.
  • Figure 63 shows nucleic acid SEQ. ID. No.:125 and amino acid SEQ. ID. No.: 126.
  • Figure 64 shows nucleic acid SEQ. ID. No.:127 and amino acid SEQ. ID. No.: 128.
  • Figure 65 shows nucleic acid SEQ. ID. No.:129 and amino acid SEQ. ID. No.: 130.
  • Figure 66 shows nucleic acid SEQ. ID. No.: 131 and amino acid SEQ. ID. No.: 132.
  • Figure 67 shows nucleic acid SEQ. ID. No.: 133 and amino acid SEQ. ID. No.: 134.
  • Figure 68 shows nucleic acid SEQ. ID. No.: 135 and amino acid SEQ. ID. No.: 136.
  • Figure 69 shows nucleic acid SEQ. ID. No.:137 and amino acid SEQ. ID. No.: 138.
  • Figure 70 shows nucleic acid SEQ. ID. No.:139 and amino acid SEQ. ID. No.: 140.
  • Figure 72 shows nucleic acid SEQ. ID. No.:143 and amino acid SEQ. ID. No.: 144.
  • Figure 73 shows nucleic acid SEQ. ID. No.:145 and - ⁇ * « •• ⁇ »• PCT/US2003/032722
  • Figure 74 shows nucleic acid SEQ. ID. No.:147 and amino acid SEQ. ID. No.: 148.
  • Figure 75 shows nucleic acid SEQ. ID No.: 149 and amino acid SEQ. ID. No.: 150.
  • Figure 76 shows nucleic acid SEQ. ID No.: 151 and amino acid SEQ. ID. No.: 152.
  • Figure 77 shows nucleic acid SEQ. ID No.: 153 and amino acid SEQ. ID. No.: 154.
  • Figure 78 shows nucleic acid SEQ. ID No.: 155 and amino acid SEQ. ID. No.: 156.
  • Figure 79 shows nucleic acid SEQ. ID No.: 157 and amino acid SEQ. ID. No.: 158.
  • Figure 80 shows nucleic acid SEQ. ID No.: 159 and amino acid SEQ. ID. No.: 160.
  • Figure 81 shows nucleic acid SEQ. ID No.: 161 and amino acid SEQ. ID. No.: 162.
  • Figure 82 shows nucleic acid SEQ. ID No.: 163 and amino acid SEQ. ID. No.: 164.
  • Figure 83 shows nucleic acid SEQ. ID No.: 165 and amino acid SEQ. ID. No.: 166.
  • Figure 84 shows nucleic acid SEQ. ID No.: 167 and amino acid SEQ. ID. No.: 168.
  • Figure 85 shows nucleic acid SEQ. ID No.: 169 and amino acid SEQ. ID. No.: 170.
  • Figure 86 shows nucleic acid SEQ. ID No.: 171 and amino acid SEQ. ID. No.: 172.
  • Figure 87 shows nucleic acid SEQ. ID No.: 173 and amino acid SEQ. ID. No.: 174.
  • Figure 88 shows nucleic acid SEQ. ID No.: 175 and amino acid SEQ. ID. No.: 176.
  • Figure 89 shows nucleic acid SEQ. ID No.: 177 and amino acid SEQ. ID. No.: 178.
  • Figure 90 shows nucleic acid SEQ. ID No.: 179 and amino acid SEQ. ID. No.: 180.
  • Figure 91 shows nucleic acid SEQ. ID No.: 181 and amino acid SEQ. ID. No.: 182.
  • Figure 92 shows nucleic acid SEQ. ID No.: 183 and amino acid SEQ. ID. No.: 184.
  • Figure 93 shows nucleic acid SEQ. ID No.: 185 and amino acid SEQ. ID. No.: 186.
  • Figure 94 shows nucleic acid SEQ. ID No.: 187 and amino acid SEQ. ID. No.: 188.
  • Figure 95 shows nucleic acid SEQ. ID No.: 189 and amino acid SEQ. ID. No.: 190.
  • Figure 96 shows nucleic acid SEQ. ID No.: 191 and amino acid SEQ. ID. No.: 192.
  • Figure 97 shows nucleic acid SEQ. ID No.: 193 and amino acid SEQ. ID. No.: 194.
  • Figure 98 shows nucleic acid SEQ. ID No.: 195 and amino acid SEQ. ID. No.: 196.
  • Figure 99 shows nucleic acid SEQ. ID No.: 197 and amino acid SEQ. ID. No.: 198.
  • Figure 100 shows nucleic acid SEQ. ID No.: 199 and amino acid SEQ. ID. No.: 200.
  • Figure 101 shows nucleic acid SEQ. ID No.: 201 and amino acid SEQ. ID. No.: 202.
  • Figure 102 shows nucleic acid SEQ. ID No.: 203 and amino acid SEQ. ID. No.: 204.
  • Figure 103 shows nucleic acid SEQ. ID No.: 205 and amino acid SEQ. ID. No.: 206.
  • Figure 104 shows nucleic acid SEQ. ID No.: 207 and amino acid SEQ. ID. No.: 208.
  • Figure 105 shows nucleic acid SEQ. ID No.: 209 and amino acid SEQ. ID. No.: 210.
  • Figure 106 shows nucleic acid SEQ. ID No.: 211 and amino acid SEQ. ID. No.: 212.
  • Figure 107 shows nucleic acid SEQ. ID No.: 213 and amino acid SEQ. ID. No.: 214.
  • Figure 108 shows nucleic acid SEQ. ID No.: 215 and amino acid SEQ. ID. No.: 216.
  • Figure 109 shows nucleic acid SEQ. ID No.: 217 and amino acid SEQ. ID. No.: 218.
  • Figure 110 shows nucleic acid SEQ. ID No.: 219 and amino acid SEQ. ID. No.: 220.
  • Figure 111 shows nucleic acid SEQ. ID No.: 221 and amino acid SEQ. ID. No.: 222.
  • Figure 112 shows nucleic acid SEQ. ID No.: 223 and amino acid SEQ. ID. No.: 224.
  • Figure 113 shows nucleic acid SEQ. ID No.: 225 and amino acid SEQ. ID. No.: 226.
  • Figure 114 shows nucleic acid SEQ. ID No.: 227 and amino acid SEQ. ID. No.: 228.
  • Figure 115 shows nucleic acid SEQ. ID No.: 229 and amino acid SEQ. ID. No.: 230.
  • Figure 116 shows nucleic acid SEQ. ID No.: 231 and amino acid SEQ. ID. No.: 232.
  • Figure 117 shows nucleic acid SEQ. ID No.: 233 and a TMino acid SEQ. ID. No.: 234.
  • Figure 118 shows nucleic acid SEQ. ID No.: 235 and amino acid SEQ. ID. No.: 236.
  • Figure 119 shows nucleic acid SEQ. ID No.: 237 and amino acid SEQ. ID. No.: 238.
  • Figure 120 shows nucleic acid SEQ. ID No.: 239 and amino acid SEQ. ID. No.: 240.
  • Figure 121 shows nucleic acid SEQ. ID No.: 241 and amino acid SEQ. ID. No.: 242.
  • Figure 122 shows nucleic acid SEQ. ID No.: 243 and amino acid SEQ. ID. No.: 244.
  • Figure 123 shows nucleic acid SEQ. ID No.: 245 and amino acid SEQ. ID. No.: 246.
  • Figure 124 shows nucleic acid SEQ. ID No.: 247 and amino acid SEQ. ID. No.: 248.
  • Figure 125 shows nucleic acid SEQ. ID No.: 249 and amino acid SEQ. ID. No.: 250.
  • Figure 126 shows nucleic acid SEQ. ID No.: 251 and amino acid SEQ. ID. No.: 252.
  • Figure 127 shows nucleic acid SEQ. ID No.: 253 and amino acid SEQ. ID. No.: 254.
  • Figure 128 shows nucleic acid SEQ. ID No.: 255 and amino acid SEQ. ID. No.: 256.
  • Figure 129 shows nucleic acid SEQ. ID No.: 257 and amino acid SEQ. ID. No.: 258.
  • Figure 130 shows nucleic acid SEQ. ID No.: 259 and amino acid SEQ. ID. No.: 260,
  • Figure 131 shows nucleic acid SEQ. ID No.: 261 and amino acid SEQ. ID. No.: 262.
  • Figure 132 shows nucleic acid SEQ. ID No.: 263 and amino acid SEQ. ID. No.: 264.
  • Figure 133 shows nucleic acid SEQ. ID No.: 265 and amino acid SEQ. ID. No.: 266.
  • Figure 134 shows nucleic acid SEQ. ID No.: 267 and amino acid SEQ. ID. No.: 268.
  • Figure 135 shows nucleic acid SEQ. ID No.: 269 and amino acid SEQ. ID. No.: 270.
  • Figure 136 shows nucleic acid SEQ. ID No.: 271 and amino acid SEQ. ID. No.: 272.
  • Figure 137 shows nucleic acid SEQ. ID No. : 273 and amino acid SEQ. ID. No.: 274.
  • Figure 138 shows nucleic acid SEQ. ID No. : 275 and amino acid SEQ. ID. No.: 276.
  • Figure 139 shows nucleic acid SEQ. ID No. : 277 and amino acid SEQ. ID. No.: 278.
  • Figure 140 shows nucleic acid SEQ. ID No.: 279 and amino acid SEQ. ID. No.: 280.
  • Figure 141 shows nucleic acid SEQ. ID No. : 281 and amino acid SEQ. ID. No.: 282.
  • Figure 142 shows nucleic acid SEQ. ID No . : 283 and amino acid SEQ. ID. No.: 284.
  • Figure 143 shows nucleic acid SEQ. ID No.: 285 and amino acid SEQ. ID. No.: 286.
  • Figure 144 shows nucleic acid SEQ. ID No.: 287 and amino acid SEQ. ID. No.: 288.
  • Figure 145 shows nucleic acid SEQ. ID No . : 289 and amino acid SEQ. ID. No.: 290.
  • Figure 146 shows nucleic acid SEQ. ID No.: 291 and amino acid SEQ. ID. No.: 292.
  • Figure 147 shows nucleic acid SEQ. ID No.: 293 and amino acid SEQ. ID. No.: 294.
  • Figure 148 shows nucleic acid SEQ. ID No.: 295 and amino acid SEQ. ID. No.: 296.
  • Figure 149 shows nucleic acid SEQ. ID No.: 297 and amino acid SEQ. ID. No.: 298.
  • Figure 151 shows a comparison of Sequence Groups.
  • Figure 152 illustrates alignment of full length clones.
  • Figure 153 shows a procedure used for cloning of cytochrome p450 cDNA fragments by PCR
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, or sense or anti-sense, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.
  • operably linked refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.
  • a nucleic acid expression control sequence such as a promoter, signal sequence, or array of transcription factor binding sites
  • Recombinant when used with reference to a cell indicates that the cell replicates a heterologous nucleic acid, expresses said nucleic acid or expresses a peptide, heterologous peptide, or protein encoded by a heterologous nucleic acid.
  • Recombinant cells can express genes or gene fragments in either the sense or antisense form that are not found within the native (non- recombinant) form of the cell.
  • Recombinant cells can also express genes that are found in the native form of the cell, but wherein the genes are modified and re- introduced into the cell by artificial means .
  • a “structural gene” is that portion of a gene comprising a DNA segment encoding a protein, polypeptide or a portion thereof, and excluding the 5* sequence which drives the initiation of transcription.
  • the structural gene may alternatively encode a nontranslatable product.
  • the structural gene may be one which is normally found in the cell or one which is not normally found in the cell or cellular location wherein it is introduced, in which case it is termed a "heterologous gene".
  • a heterologous gene may be derived in whole or in part from any source known to the art, including a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA or chemically synthesized DNA.
  • a structural gene may contain one or more modifications that could effect biological activity or its characteristics, the biological activity or the chemical structure of the expression product, the rate of expression or the manner of expression control. Such modifications include, but are not limited to, mutations, insertions, deletions and substitutions of one or more nucleotides.
  • the structural gene may constitute an uninterrupted coding sequence or it may include one or more introns, bounded by the appropriate splice junctions.
  • the structural gene may be translatable or non-translatable, including in an anti- sense orientation.
  • the structural gene may be a composite of segments derived from a plurality of sources and from a plurality of gene sequences (naturally occurring or synthetic, where synthetic refers to DNA that is chemically synthesized) .
  • “Derived from” is used to mean taken, obtained, received, traced, replicated or descended from a source (chemical and/or biological) .
  • a derivative may be produced by chemical or biological manipulation (including, but not limited to, substitution, addition, insertion, deletion, extraction, isolation, mutation and replication) of the original source.
  • “Chemically synthesized”, as related to a sequence of DNA, means that portions of the component nucleotides were assembled in vitro.
  • Manual chemical synthesis of DNA may be accomplished using well established procedures (Caruthers, Methodology of DNA and RNA Sequencing, (1983), Weissman (ed.), Praeger Publishers, New York, Chapter 1) ; automated chemical synthesis can be performed using one of a number of commercially available machines.
  • Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of' Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection.
  • NCBI Basic Local Alignment Search Tool (Altschul et al., 1990) is available from several sources, including the National Center for Biological Information (NCBI, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. It can be accessed at htp: //www. cbi.nlm. ih.gov/BLAST/ . A description of how to determine sequence identity using this program is available at http: //www.ncbi.nlm.nih.gov/BLAST/blast help.html.
  • substantially amino acid identity or “substantial amino acid sequence identity” as applied to amino acid sequences and as used herein denote a characteristic of a polypeptide, wherein the peptide comprises a sequence that has at least 70 percent sequence identity, preferably 80 percent amino acid sequence identity, more preferably 90 percent amino acid sequence identity, and most preferably at least 99 to 100 percent sequence identity as compared to a reference group over region corresponding to the first amino acid following the cytochrome p450 motif GXRXCX(G/A) to the stop codon of the translated peptide.
  • nucleic acid identity or “substantial nucleic acid sequence identity” as applied to nucleic acid sequences and as used herein denote a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 75 percent sequence identity, preferably 81 percent amino acid sequence identity, more preferably at least 91 percent sequence identity, and most preferably at least 99 to 100 percent sequence identity as compared to a reference group over region corresponding to the first nucleic acid following the cytochrome p450 motif GXRXCX(G/A) to the stop codon of the translated peptide.
  • stringent conditions are sequence-dependent and will be different in different circumstances.
  • stringent conditions are selected to be about 5 * C to about 20 "C, usually about 10 'C to about 15 'C, lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
  • Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a matched probe.
  • stringent conditions will be those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 60 * C.
  • stringent conditions will include an initial wash in 6xSSC at 42 "C followed by one or more additional washes in 0.2xSSC at a temperature of at least about 55 "C, typically about 60 * C and often about 65 * C.
  • Nucleotide sequences are also substantially identical for purposes of this invention when the polypeptides and/or proteins which they encode are substantially identical. Thus, where one nucleic acid sequence encodes essentially the same polypeptide as a second nucleic acid sequence, the two nucleic acid sequences are substantially identical, even if they would not hybridize under stringent conditions due to degeneracy permitted by the genetic code (see, Darnell et al. (1990) Molecular Cell Biology, Second Edition Scientific American Books W. H. Freeman and Company New York for an explanation of codon degeneracy and the genetic code) .
  • Protein purity or homogeneity can be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualization upon staining. For certain purposes high resolution may be needed and HPLC or a similar means for purification may be utilized.
  • vector is used in reference to nucleic acid molecules that transfer DNA segment (s) into a cell.
  • a vector may act to replicate DNA and may reproduce independently in a host cell.
  • vector is sometimes used interchangeably with “vector.”
  • expression vector refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional) , and a ribosome binding site, often along with other sequences.
  • Eucaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
  • a nucleic acid may be inserted into plant cells, for example, by any technique such as in vivo inoculation or by any of the known in vitro tissue culture techniques to produce transformed plant cells that can be regenerated into complete plants.
  • the insertion into plant cells may be by in vitro inoculation by pathogenic or non-pathogenic A. tumefaciens .
  • Other such tissue culture techniques may also be employed.
  • Plant tissue includes differentiated and undifferentiated tissues of plants, including, but not limited to, roots, shoots, leaves, pollen, seeds, tumor tissue and various forms of cells in culture, such as single cells, protoplasts, embryos and callus tissue.
  • the plant tissue may be in planta or in organ, tissue or cell culture .
  • Plant cell as used herein includes plant cells in planta and plant cells and protoplasts in culture.
  • cDNA or “complementary DNA” generally refers to a single stranded DNA molecule with a nucleotide sequence that is complementary to an RNA molecule. cDNA is formed by the action of the enzyme reverse transcriptase on an RNA template.
  • RNA was extracted from Nicotiana tissue of converter and non- converter Nicotiana lines . The extracted RNA was then used to create cDNA. Nucleic acid sequences of the present invention were then generated using two strategies .
  • the poly A enriched RNA was extracted from-plant tissue and cDNA was made by reverse transcription PCR.
  • the single strand cDNA was then used to create p450 specific PCR populations using degenerate primers plus a oligo d(T) reverse primer.
  • the primer design was based on the highly conserved motifs of p450. Examples of specific degenerate primers are set forth in Figure 1. Sequence fragments from plasmids containing appropriate size inserts were further analyzed. These size inserts typically ranged from about 300 to about 800 nucleotides depending on which primers were used.
  • a cDNA library was initially constructed.
  • the cDNA in the plasmids was used to create p450 specific PCR populations using degenerate primers plus T7 primer on plasmid as reverse primer.
  • sequence fragments from plasmids containing appropriate size inserts were further analyzed.
  • Nicotiana plant lines known to produce high levels of nornicotine (converter) and plant lines having undetectable levels of nornicotine may be used as starting materials.
  • Leaves can then be removed from plants and treated with ethylene to activate p450 enzymatic activities defined herein.
  • Total RNA is extracted using techniques known in the art.
  • cDNA fragments can then be generated using PCR (RT-PCR) with the oligo d(T) primer as described in Figure 153.
  • RT-PCR PCR-PCR
  • the cDNA library can then be constructed more fully described in examples herein.
  • the conserved region of p450 type enzymes can be used as a template for degenerate primers ( Figure 75) .
  • degenerate primers p450 specific bands can be amplified by PCR. Bands indicative for p450 like enzymes can be identified by DNA sequencing. PCR fragments can be characterized using BLAST search, alignment or other tools to identify appropriate candidates.
  • Sequence information from identified fragments can be used to develop PCR primers. These primers in combination of plasmid primers in cDNA library were used to clone full length p450 genes. Large-scale Southern reverse analysis was conducted to examine the differential expression for all fragment clones obtained and in some cases full length clones. In this aspect of the invention, these large-scale reverse Southern assays can be conducted using labeled total cDNA' s from different tissues as a probe to hybridize with cloned DNA fragments in order to screen all cloned inserts.
  • Nonradioactive and radioactive were also used to characterize clones p450 fragments and full length clones.
  • Peptide specific antibodies were made against several full-length clones by deriving their amino acid sequence and selecting peptide regions that were antigenic and unique relative to other clones. Rabbit antibodies were made to synthetic peptides conjugated to a carrier protein. Western blotting analyses or other immunological methods were performed on plant tissue using these antibodies.
  • Nucleic acid sequences identified as described above can be examined by using virus induced gene silencing technology (VIGS, Baulcombe, Current Opinions in Plant Biology, 1999, 2:109-113).
  • Peptide specific antibodies were made for several full-length clones by deriving their amino acid sequence and selecting peptide regions that were potentially antigenic and were unique relative to other clones. Rabbit antibodies were made to synthetic petides conjugated to a carrier protein. Western blotting analyses were perfomed using these antibodies. ⁇ • * , ⁇ *. .*, . «... TM . .,-terrorism ⁇ _... .- .. conjugate 3. n0 « 32,72 11 2
  • RNAi interfering RNA technology
  • Plants may be transformed using RNAi techniques, antisense techniques, or a variety of other methods described.
  • Plants may be transformed using Agrobacterium technology, see US Patent 5,177,010 to University of Toledo, 5,104,310 to Texas A&M, European Patent Application 0131624B1, European Patent Applications 120516, 159418B1, European Patent Applications 120516, 159418B1 and 176,112 to Schilperoot, US Patents 5,149,645, 5,469,976, 5,464,763 and 4,940,838 and 4,693,976 to Schilperoot, European Patent Applications 116718, 290799, 320500 all to MaxPlanck, European Patent Applications 604662 and 627752 to Japan Nicotiana, European Patent Applications 0267159, and 0292435 and US Patent 5,231,019 all to Ciba Geigy, US Patents 5,463,174 and 4,762,785 both to Calgene, and US Patents 5,004,863 and 5,159,135 both to Agracetus .
  • transformation technology includes whiskers technology, see U.S. Patents 5,302,523 and 5,464,765 both to Zeneca. Electroporation technology has also been used to transform plants, see WO 87/06614 to Boyce Thompson Institute, 5,472,869 and 5,384,253 both to Dekalb, WO9209696 and W09321335 both to PGS . All of these transformation patents and publications are incorporated by reference.
  • tissue which is contacted with the foreign genes may vary as well. Such tissue would include but would not be limited to embryogenic tissue, callus tissue type I and II, hypocotyl, meristem, and the like. Almost all plant tissues may be transformed during dedifferentiation using appropriate techniques within the skill of an artisan.
  • Foreign genetic material introduced into a plant may include a selectable marker.
  • selectable markers include but are not limited to aminoglycoside phosphotransferase gene of transposon Tn5 (Aph II) which encodes resistance to the antibiotics kanamycin, neomycin and G418, as well as those genes which code for resistance or tolerance to glyphosate; hygromycin; methotrexate; phosphinothricin (bar) ; imidazolinones, sulfonylureas and triazolopyrimidine herbicides, such as chlorosulfuron; bromoxynil, dalapon and the like.
  • reporter gene In addition to a selectable marker, it may be desirous to use a reporter gene. In some instances a reporter gene may be used without a selectable marker. Reporter genes are genes which are typically not present or expressed in the recipient organism or tissue. The reporter gene typically encodes for a protein which provide for some phenotypic change or enzymatic property. Examples of such genes are provided in K. Weising et al. Ann. Rev. Genetics, 22, 421 (1988), which is incorporated herein by reference. Preferred reporter genes include without limitation glucuronidase (GUS) gene and GFP genes .
  • GUS glucuronidase
  • the expression of the structural gene may be assayed by any means known to the art, and expression may be measured as mRNA transcribed, protein synthesized, or the amount of gene silencing that occurs (see U.S. Patent No. 5,583,021 which is hereby incorporated by reference).
  • Techniques are known for the in vitro culture of plant tissue, and in a number of cases, for regeneration into whole plants (EP Appln No. 88810309.0). Procedures for transferring the introduced expression complex to commercially useful cultivars are known to those skilled in the art.
  • plant cells expressing the desired level of p450 enzyme are obtained, plant tissues and whole plants can be regenerated therefrom using methods and techniques well-known in the art. The regenerated plants are then reproduced by conventional means and the introduced genes can be transferred to other strains and cultivars by conventional plant breeding techniques.
  • Plants were seeded in pots and grown in a greenhouse for 4 weeks.
  • the 4 week old seedlings were transplanted into individual pots and grown in the greenhouse for 2 months.
  • the plants were watered 2 times a day with water containing 150ppm NPK fertilizer during growth.
  • the expanded green leaves were detached from plants to do the ethylene treatment described below.
  • Tobacco line 78379 which is a burley tobacco line released by the University of Kentucky was used as a source of plant material.
  • One hundred plants were cultured as standard in the art of growing tobacco and transplanted and tagged with a distinctive number (1- 100) . Fertilization and field management were conducted as recommended.
  • Nicotiana line 4407 which is a burley line was used as a source of plant material. Uniform and representative plants (100) were selected and tagged. Of the 100 plants 97 were non-converters and three were converters. Plant number 56 had the least amount of conversion (1.2%) and plant number 58 had the highest level of conversion (96%) . Self-pollenated seeds and crossed seeds were made with these two plants.
  • Plants from selfed-58 segregated with 3:1 converter to non-converter ratio were identified as homozygous converter and nonconverter plant lines, respectively.
  • the stable conversion of 58-33 was confirmed by analysis of its progenies of next generation.
  • PBLB01 is a burley line developed by ProfiGen, Inc. and was used as a source of plant material.
  • the converter plant was selected from foundation seeds of PBLB01.
  • Green leaves were detached from 2-3 month greenhouse grown plants and sprayed with 0.3% ethylene solution (Prep brand Ethephon (Rhone-Poulenc) ) . Each sprayed leaf was hung in a curing rack equipped with humidifier and covered with plastic. During the treatment, the sample leaves were periodically sprayed with the ethylene solution. Approximately 24-48 hour post ethylene treatment, leaves were collected for RNA extraction. Another sub-sample was taken for metabolic constituent analysis to determine the concentration of leaf metabolites and more specific constituents of interest such as a variety of alkaloids.
  • alkaloids analysis could be performed as follows. Samples (0.1 g) were shaken at 150 rpm with 0.5 ml 2N NaOH, and a 5 ml extraction solution which contained quinoline as an internal standard and methyl t- butyl ether. Samples were analyzed on a HP 6890 GC equipped with a FID detector. A temperature of 250 "C was used for the detector and injector. An HP column (30m- 0.32nm-l-m) consisting of fused silica crosslinked with 5% phenol and 95% methyl silicon was used at a temperature gradient of 110-185 * C at 10'C per minute. The column was operated at 100 "C with a flow rate of 1.7cm 3 min -1 with a split ratio of 40:1 with a 2-1 injection volume using helium as the carrier gas.
  • RNA extractions Middle leaves from 2 month old greenhouse grown plants were treated with ethylene as described. The 0 and 24-48 hours samples were used for RNA extraction. In some cases, leaf samples under the senescence process were taken from the plants 10 days post flower-head removal. These samples were also used for extraction. Total RNA was isolated using Rneasy Plant
  • the tissue sample was ground under liquid nitrogen to a fine powder using a DEPC treated mortar and pestle. Approximately 100 milligrams of ground tissue were transferred to a sterile 1.5 ml eppendorf tube. This sample tube was placed in liquid nitrogen until all samples were collected. Then, 450 ⁇ -l of Buffer RLT as provided in the kit (with the addition of Mercaptoethanol) was added to each individual tube. The sample was vortexed vigorously and incubated at 56° C for 3 minutes. The lysate was then, applied to the QIAshredderTM spin column sitting in a 2-ml collection tube, and centrifuged for 2 minutes at maximum speed. The flow through was collected and 0.5 volume of ethanol was added to the cleared lysate.
  • the sample is mixed well and transferred to an Rneasy® mini spin column sitting in a 2 ml collection tube.
  • the sample was centrifuged for 1 minute at 10,000rpm.
  • 700 ⁇ l of buffer RWl was pipetted onto the Rneasy® column and centrifuged for 1 minute at 10,000rpm.
  • Buffer RPE was pipetted onto the Rneasy® column in a new collection tube and centrifuged for 1 minute at 10,000 rpm.
  • Buffer RPE was again, added to the Rneasy® spin column and centrifuged for 2 minutes at maximum speed to dry the membrane. To eliminate any ethanol carry over, the membrane was placed in a separate collection tube and centrifuged for an additional 1 minute at maximum speed.
  • the Rneasy® column was transferred into a new 1.5 ml collection tube, and 40 ⁇ l of Rnase-free water was pipetted directly onto the Rneasy® membrane. This final elute tube was centrifuged for 1 minute at 10,000rpm. Quality and quantity of total RNA was analyzed by denatured formaldehyde gel and spectrophotometer.
  • RNA was isolated using OligotexTM poly A+ RNA purification kit (Qiagen Inc.) following manufacture's protocol. About 200 ⁇ g total RNA in 250 ⁇ l maximum volume was used. A volume of 250 ⁇ l of Buffer OBB and 15 ⁇ l of OligotexTM suspension was added to the 250 ⁇ l of total RNA. The contents were mixed thoroughly by pipetting and incubated for 3 minutes at 70 'C on a heating block. The sample was then, placed at room temperature for approximately 20 minutes. The oligotex:mRNA complex was pelleted by centrifugation for 2 minutes at maximum speed. All but 50 ⁇ l of the supernatant was removed from the microcentrifuge tube. The sample was treated further by OBB buffer.
  • the oligotex :mRNA pellet was resuspended in 400 ⁇ l of Buffer OW2 by vortexing. This mix was transferred onto a small spin column placed in a new tube and centrifuged for 1 minute at maximum speed. The spin column was transferred to a new tube and an additional 400 ⁇ l of Buffer OW2 was added to the column. The tube was then centrifuged for
  • First strand cDNA was produced using Superscript reverse transcriptase following manufacturer' s protocol (Invitrogen, Carlsbad, California) .
  • the poly A+ enriched RNA/oligo dT primer mix consisted of less than 5 ⁇ g of total RNA, 1 ⁇ l of lO M dNTP mix, 1 ⁇ l of Oligo d(T) 12 - ⁇ . (0.5 ⁇ g/ ⁇ l), and up to 10 ⁇ l of DEPC-treated water. Each sample was incubated at 65 'C for 5 minutes, then placed on ice for at least 1 minute.
  • reaction mixture was prepared by adding each of the following components in order: 2 ⁇ l 10X RT buffer, 4 ⁇ l of 25 mM MgC12, 2 ⁇ l of 0.1 M DTT, and 1 ⁇ l of RNase OUT Recombinant RNase Inhibitor. An addition of 9 ⁇ l of reaction mixture was pipetted to each RNA/primer mixture and gently mixed. It was incubated at 42 'C for
  • Reaction conditions were 94 * C for 2 minutes and then performed 40 cycles of PCR at 94 * C for 1 minute, 45" to 60 * C for 2 minutes, 72'C for 3 minutes with a 72 'C extension for an extra 10 min.
  • PCR fragments from Example 3 were ligated into a pGEM-T® Easy Vector (Promega, Madison, Wisconsin) following manufacturer's instructions.
  • the ligated product was transformed into JM109 competent cells and plated on LB media plates for blue/white selection. Colonies were selected and grown in a 96 well plate with 1.2 ml of LB media overnight at 37 'C. Frozen stock was generated for all selected colonies.
  • Plasmid DNA from plates were purified using Beckman' s Biomeck 2000 miniprep robotics with Wizard SV Miniprep® kit (Promega) . Plasmid DNA was eluted with 100 ⁇ l_water and stored in a 96 well plate.
  • Plasmids were digested by EcoRI and were analyzed using 1% agarose gel to confirm the DNA quantity and size of inserts.
  • the plasmids containing a 400-600 bp insert were sequenced using an CEQ 2000 sequencer (Beckman, Fullerton, California) .
  • the sequences were aligned with GenBank database by BLAST search.
  • the p450 related fragments were identified and further analyzed.
  • p450 fragments were isolated from substraction libraries. These fragments were also analyzed as described above.
  • a cDNA library was constructed by preparing total RNA from ethylene treated leaves as follows. First, total RNA was extracted from ethylene treated leaves of tobacco line 58-33 using a modified acid phenol and chloroform extraction protocol. Protocol was modified to use one gram of tissue that was ground and subsequently vortexed in 5 ml of extraction buffer (100 mM Tris-HCl, pH 8.5; 200 mM NaCl; lOmM EDTA; 0.5% SDS) to which 5 ml phenol (pH5.5) and 5 ml chloroform was added. The extracted sample was centrifuged and the supernatant was saved. This extraction step was repeated 2-3 more times until the supernatant appeared clear.
  • extraction buffer 100 mM Tris-HCl, pH 8.5; 200 mM NaCl; lOmM EDTA; 0.5% SDS
  • poly A+ RNA was used as template to produce a cDNA library employing cDNA synthesis kit, ZAP-cDNA® synthesis kit, and ZAP-cDNA® Gigapack® III gold cloning kit (Stratagene, La Jolla, California) .
  • the method involved following the manufacture's protocol as specified.
  • Approximately 8 ⁇ g of poly A+ RNA was used to construct cDNA library.
  • Analysis of the primary library revealed about 2.5 x 10 6 - lx 10 7 pfu.
  • a quality background test of the library was completed by complementation assays using IPTG and X-gal, where recombinant plaques was expressed at more than 100-fold above the background reaction.
  • a more quantitative analysis of the library by random PCR showed that average size of insert cDNA was approximately 1.2 kb.
  • the method used a two-step PCR method as followed.
  • reverse primers were designed based on the preliminary sequence information obtained from p450 fragments.
  • the designed reverse primers and T3 (forward) primers were used amplify corresponding genes from the cDNA library.
  • PCR reactions were subjected to agarose electrophoresis and the corresponding bands of high molecular weight were excised, purified, cloned and sequenced.
  • new primers designed from 5'UTR or the start coding region of p450 as the forward primers together with the reverse primers (designed from 3'UTR of p450) were used in the subsequent PCR to obtain full-length p450 clones.
  • the p450 fragments were generated by PCR amplification from the constructed cDNA library as described in Example 3 with the exception of the reverse primer.
  • the T7 primer located on the plasmid downstream of cDNA inserts was used as a reverse primer. PCR fragments were isolated, cloned and sequenced as described in Example 4.
  • Full-length p450 genes were isolated by PCR method from constructed cDNA library. Gene specific reverse primers (designed from the downstream sequence of p450 fragments) and a forward primer (T3 on library plasmid) were used to clone the full length genes. PCR fragments were isolated, cloned and sequenced. If necessary, second step PCR was applied. In the second step, new forward primers designed from 5'UTR of cloned p450s together with the reverse primers designed from 3'UTR of p450 clones were used in the subsequent PCR reactions to obtain full-length p450 clones. The clones were subsequently sequenced.
  • EXAMPLE 6 CHARACTERIZATION OF CLONED FRAGMENTS - REVERSE SOUTHERN BLOTTING ANALYSIS
  • Nonradioactive large scale reverse southern blotting assays were performed on all p450 clones identified in above examples to detect the differential expression. It was observed that the level of expression among different p450 clusters was very different. Further real time detection was conducted on those with high expression.
  • the inserts were PCR amplified from each plasmid using the sequences located on both arms of p-GEM plasmid, T3 and SP6, as primers.
  • the PCR products were analyzed by running on a 96 well Ready- to-run agarose gels. The confirmed inserts were dotted on two nylon membranes. One membrane was hybridized with converter probe and the other with nonconverter probe.
  • the membranes were hybridized and washed following manufacture's instruction with the modification of washing stringency (Enzo MaxSenceTM kit, Enzo Diagnostics, Inc, Farmingdale, NY) .
  • the membranes were prehybridized with hybridization buffer (2x SSC buffered formamide, containing detergent and hybridization enhancers) at 42°C for 30 min and hybridized with lO ⁇ l denatured probe overnight at 42°C.
  • the membranes then were washed in IX hybridization wash buffer 1 time at room temperature for 10 min and 4 times at 68°C for 15 min. The membranes were ready for the detection.
  • EXAMPLE 7 CHARACTERIZATION OF CLONES - NORTHERN BLOT ANALYSIS
  • a random priming method was used to prepare probes from cloned p450 (MegaprimeTM DNA Labelling Systems, Amersham Biosciences) .
  • the following components were mixed: 25ng denatured DNA template; 4ul of each unlabeled dTTP, dGTP and dCTP; 5ul of reaction buffer; P 32 -labelled dATP and 2ul of Klenow I; and H 2 0, to bring the reaction to 50 ⁇ l.
  • the mixture was incubated in 37 °C for 1-4 hours, then stopped with 2 ⁇ l of 0.5 M EDTA.
  • the probe was denatured by incubating at 95°C for 5 minutes before use.
  • RNA samples were prepared from ethylene treated and non-treated fresh leaves of several pairs of tobacco lines. In some cases poly A+ enriched RNA was used. Approximately 15 ⁇ g total RNA or 1.8 ⁇ g mRNA
  • RNA samples were subjected to electrophoresis on a formaldehyde gel (1 % Agarose, 1 x MOPS, 0.6 M Formaldehyde) with 1XMOP buffer (0.4 M Morpholinopropanesulfonic acid; 0.1 M Na-acetate-3 x H20; 10 mM EDTA; adjust to pH 7.2 with NaOH) .
  • RNA was transferred to a Hybond-N+ membrane (Nylon, Amersham Pharmacia Biotech) by capillary method in 10 X SSC buffer (1.5 M NaCl; 0.15 M Na-citrate) for 24 hours.
  • Membranes with RNA samples were UV-crosslinked (auto crosslink setting, 254 nm, Stratagene, Stratalinker) before hybridization.
  • the membrane was prehybridized for 1-4 hours at 42°C with 5-10 ml prehybridization buffer (5 x SSC; 50
  • EXAMPLE 8 IMMUNODETECTION OF p450S ENCODED BY THE CLONED GENES
  • Peptide regions corresponding to 20-22 amino acids in length from three p450 clones were selected for 1) having lower or no homology to other clones and 2) having good hydrophilicity and antigenicity.
  • the amino acid sequences of the peptide regions selected from the respective p450 clones are listed below.
  • the synthesized peptides were conjugated with KHL and then injected into rabbits. Antisera were collected 2 and 4 weeks after the 4 th injection (Alpha Diagnostic Intl., Inc. San Antonio, TX) .
  • Antisera were examined for crossreactivity to target proteins from tobacco plant tissue by Western Blot analysis. Crude protein extracts were obtained from ethylene treated (0 to 40 hours) middle leaves of converter and nonconverter lines. Protein concentrations of the extracts were determined using RC DC Protein Assay Kit (BIO-RAD) following the manufacturer's protocol.
  • p450 fragments were sequenced in conjunction with Northern blot analysis to determine their structural relatedness.
  • the approach used utilized forward primers based either of two common p450 motifs located near the carboxyl-terminus of the p450 genes.
  • the forward primers corresponded to cytochrome p450 motifs FXPERF or GRRXCP (A/G) as denoted in Figure 1.
  • the reverse primers used standard primers from either the plasmid, SP6 or T7 located on both arms of pGEMTM plasmid, or a poly A tail. The protocol used is described below.
  • Spectrophotometry was used to estimate the concentration of starting double stranded DNA following the manufacturer's protocol (Beckman Coulter).
  • the template was diluted with water to the appropriate concentration, denatured by heating at 95' C for 2 minutes, and subsequently placed on ice.
  • the sequencing reaction was prepared on ice using 0.5 to lO ⁇ l of denatured DNA template, 2 ⁇ l of 1.6 pmole of the forward primer, 8 ⁇ l of DTCS Quick Start Master Mix and the total volume brought to 20 ⁇ l with water.
  • the thermocycling program consisted of 30 cycles of the follow cycle: 96 * C for 20 seconds, 50 * C for 20 seconds, and 60' C for 4 minutes followed by holding at 4 * C.
  • the sequence was stopped by adding 5 ⁇ l of stop buffer (equal volume of 3M NaOAc and lOOmM EDTA and 1 ⁇ l of 20 mg/ml glycogen) .
  • the sample was precipitated with 60 ⁇ l of cold 95% ethanol and centrifuged at 6000g for 6 minutes. Ethanol was discarded. The pellet was 2 washes with 200 ⁇ l of cold 70% ethanol. After the pellet was dry, 40 ⁇ l of SLS solution was added and the pellet was resuspended. A layer of mineral oil was over laid. The sample was then, placed on the CEQ 8000 Automated Sequencer for further analysis.
  • nucleic acid sequence was re-sequenced in both directions using forward primers to the FXPERF or GRRXCP(A/G) region of the p450 gene or reverse primers to either the plasmid or poly A tail. All sequencing was performed at least twice in both directions.
  • nucleic acid sequences of cytochrome p450 fragments were compared to each other from the coding region corresponding to the first nucleic acid after the region encoding the GRRXCP (A/G) motif through to the stop codon. This region was selected as an indicator of genetic diversity among p450 proteins. A large number of genetically distinct p450 genes, in excess of 70 genes, were observed, similar to that of other plant species. Upon comparison of nucleic acid sequences, it was found that the genes could be placed into distinct sequences groups based on their sequence identity. It was found that the best unique grouping of p450 members was determined to be those sequences with 75% nucleic acid identity or greater (shown in Table I) . Reducing the percentage identity resulted in significantly larger groups.
  • a preferred grouping was observed for those sequences with 81% nucleic acid identity or greater, a more preferred grouping 91% nucleic acid identity or greater, and a most preferred grouping for those sequences 99% nucleic acid identity of greater. Most of the groups contained at least two members and frequently three or more members. Others were not repeatedly discovered suggesting that approach taken was able to isolated both low and high expressing mRNA in the tissue used.
  • cytochrome p450 groups were found to contain nucleic acid sequence identity to previously tobacco cytochrome genes that genetically distinct from that within the group.
  • Group 23 showed nucleic acid identity, within the parameters used for Table I, to prior GenBank sequences of GI: 1171579 (CAA64635) and GI: 14423327 (or AAK62346) by Czernic et al and Ralston et al, respectively.
  • GI: 1171579 had nucleic acid identity to Group 23 members ranging 96.9% to 99.5% identity to members of Group 23 while GI: 14423327 ranged 95.4% to 96.9% identity to this group.
  • the members of Group 31 had nucleic acid identity ranging from 76.7% to 97.8% identity to the GenBank reported sequence of GI: 14423319 (AAK62342) by Ralston et al. None of the other p450 identity groups of Table 1 contained parameter identity, as used in Table 1, to Nicotiana p450s genes reported by Ralston et al, Czernic et al., Wang et al or LaRosa and Smigocki,
  • D58-BG7 (SEQ ID No.:l), D58-AB1 (SEQ ID No. :3); D58-BE4 (SEQ ID No. :7)
  • D35-BB7 (SEQ ID No.:23); D177-BA7 (SEQ ID No.:25); D56A-AB6 (SEQ ID No.: 27); D144-AE2 (SEQ ID No.: 29)
  • D58-AB9 SEQ ID No.: 47
  • D56-AG9 SEQ ID No.: 49
  • D56-AG6 SEQ ID No.:51
  • D35-BG11 SEQ ID No.:53
  • D35-42 D58-AB9
  • D177-BD5 (SEQ ID No.: 69); D177-BD7 (SEQ ID No.: 83) 15 D56A-AG10 (SEQ ID No.: 71); D58-BC5 (SEQ ID No.: 73); D58-AD12 (SEQ ID No.: 75)
  • D56-AC11 SEQ ID No.:77
  • D35-39 SEQ ID No.:79
  • D58-BH4 SEQ ID No.: 81
  • D56-AD6 SEQ ID No.: 87
  • D73A-AD6 (SEQ ID No.:89); D70A-BA11 (SEQ ID No.:91)
  • D70A-AB8 (SEQ ID No.:99); D70A-BH2 (SEQ ID No.:101); D70A-AA4 (SEQ ID No.:103)
  • D70A-BA1 (SEQ ID No.: 105); D70A-BA9 (SEQ ID No.:107)
  • D58-AA1 (SEQ ID No.: 121); D185-BC1 (SEQ ID No. : 133); D185-BG2 (SEQ ID No.:135)
  • EXAMPLE 10 RELATED AMINO ACID SEQUENCE IDENTITY OF ISOLATED NUCLEIC ACID FRAGMENTS
  • the amino acid sequences of nucleic acid sequences obtained for cytochrome p450 fragments from Example 8 were deduced.
  • the deduced region corresponded to the amino acid immediately after the GXRXCP (A/G) sequence motif to the end of the carboxyl-terminus, or stop codon.
  • a unique grouping was observed for those sequences with 70% amino acid identity or greater.
  • a preferred grouping was observed for those sequences with 80% amino acid identity or greater, more preferred with 90% amino acid identity or greater, and a most preferred grouping for those sequences 99% amino acid identity of greater.
  • the groups and corresponding amino acid sequences of group members are shown in Figure 2. Several of the unique nucleic acid sequences were found to have complete amino acid identity to other fragments and therefore only one member with the identical amino acid was reported.
  • the amino acid identity for Group 19 of Table II corresponded to three distinct groups based on their nucleic acid sequences.
  • the amino acid sequences of each group member and their identity is shown in Figure. 77.
  • the amino acid differences are appropriated marked.
  • At least one member of each amino acid identity group was selected for gene cloning and functional studies using plants.
  • group members that are differentially affected by ethylene treatment or other biological differences as assessed by Northern and Southern analysis were selected for gene cloning and functional studies.
  • peptide specific antibodies will be prepared on sequence identity and differential sequence.
  • D58-AB9 (SEQ ID No.: 48); D56-AG9 (SEQ ID No.: 50); D56- AG6 (SEQ ID No.:52); D35-BG11 (SEQ ID No.:54); D35-42 (SEQ ID No.: 56); D35-BA3 (SEQ ID No.: 58); D34-57 (SEQ ID No.:60); D34-52 (SEQ ID No.:62)
  • D177-BD5 (SEQ ID No.:70); D177-BD7 (SEQ ID No.:84) 16 D56A-AG10 (SEQ ID No.: 72); D58-BC5 (SEQ ID No.: 74); D58-AD12 (SEQ ID No.:76)
  • D70A-AB5 (SEQ ID No.: 96); D70A-AB8 (SEQ ID No. : 100); D70A-BH2 (SEQ ID No.:102); D70A-AA4 (SEQ ID No.:104); D70A- BA1 (SEQ ID No.: 106); D70A-BA9 (SEQ ID No.: 108)
  • All p450 genes were characterized for amino acid identity using a BLAST program comparing their full length sequences to each other and to known tobacco genes.
  • the program used the NCBI special BLAST tool (Align two sequences (bl2seq) , http: //www.ncbi .nlm.nih.gov/blast/bl2seg/bl2.html) .
  • Two sequences were aligned under BLASTN without filter for nucleic acid sequences and BLASTP for amino acid sequences. Based on their percentage amino acid identity, each sequence was grouped into identity groups where the grouping contained members that shared at least 85% identity with another member.
  • a preferred grouping was observed for those sequences with 90% amino acid identity or greater, a more preferred grouping had 95% amino acid identity or greater, and a most preferred grouping had those sequences 99% amino acid identity or greater.
  • 25 unique groups were identified and are depicted in Table III. Within the parameters used for Table III for amino acid identity, three groups were found to contain greater than 85% or greater identity to known tobacco genes.
  • Members of Group 5 had up to 96% amino acid identity for full length sequences to prior GenBank sequences of GI: 14423327 (or AAK62346) by Ralston et al .
  • Group 23 had up to 93% amino acid identity to GI: 14423328 (or AAK62347) by Ralston et al .
  • Group 24 had 92% identity to GI: 14423318 (or AAK62343) by Ralston et al.
  • D208-AD9 (SEQ. ID. No. 224); D120-AH4 (SEQ. ID. No. 180); D121-AA8 (SEQ. ID. No. 182), D122-AF10 (SEQ. ID. No. 184); D103-AH3 (SEQ. ID. No. 222); D208-AC8 (SEQ. ID. No. 218); D-235-ABI (SEQ. ID. No. 246)
  • D244-AD4 (SEQ. ID. No. 250); D244-AB6 (SEQ. ID. No. 274) ; D285-AA8; D285-AB9; D268-AE2 (SEQ. ID. No. 270)
  • D205-BE9 SEQ. ID. No. 276
  • D205-BG9 SEQ. ID. No. 202
  • D205-AH4 SEQ. ID. No. 294
  • D259-AB9 (SEQ. ID. No. 260) ; D257-AE4 (SEQ. ID. No. 268); D147-AD3 (SEQ. ID. No. 194)
  • D105-AD6 (SEQ. ID. No. 172); D215-AB5 (SEQ. ID. No. 220); D135-AE1 (SEQ. ID. No. 190) D87A-AF3 (SEQ. ID. No. 216), D210-BD4 (SEQ. ID. No. 262) D89-AB1 (SEQ. ID. No. 150); D89-AD2 (SEQ. ID. No. 152); 163-AG11 (SEQ. ID. No. 198); 163-AF12 (SEQ. ID. No. 196) D267-AF10 (SEQ. ID. No. 296); D96-AC2 (SEQ. ID. No. 160); D96-AB6 (SEQ. ID. No.
  • D207-AA5 SEQ. ID. No. 204
  • D207-AB4 SEQ. ID. No. 206
  • D207-AC4 SEQ. ID. No. 208
  • D98-AG1 SEQ. ID. No. 164
  • D98-AA1 SEQ. ID. No. 162
  • D209-AA12 SEQ. ID. No. 212
  • D209-AA11 D209-AH10
  • D D112288--AABB77 (SSEEQQ.. IIDD.. NNoo.. 118866)) ;; D D224433--AAAA22 (SEQ. ID. No. 2 24488));; DD112255--AAFF1111 ((SSEEQQ.. IIDD.. NNoo. . 222288)) D D228844--AAHH55 ( (SSEEQQ.. IIDD.. NNoo.. 229988));; D D111100--AAFF1122 (SEQ. ID. No.
  • D D228833--AACC11 (SEQ. ID. No. 272)
  • the full length genes were further grouped based on the highly conversed amino acid homology between UXXRXXZ p450 domain and GXRXC p450 domain near the end the carboxyl- terminus .
  • individual clones were aligned for their sequence homology between the conserved domains relative to each other and placed in distinct identity groups.
  • the nucleic acid sequence of the clone was unique, the amino acid sequence for the region was identical.
  • the preferred grouping was observed for those sequences with 90% amino acid identity or greater, a more preferred group had 95% amino acid identity or greater, and a most preferred grouping had those sequences 99% amino acid identity of greater.
  • the final grouping was similar to that based on the percent identity for the entire amino acid sequence of the clones except for Group 17 (of Table III) which was divided into two distinct groups.
  • Group 5 had up to 93.4% amino acid identity for full length sequences to prior GenBank sequences of GI: 14423326 (AAK62346) by Ralston et al .
  • Group 23 had up to 91.8% amino acid identity to GI:14423328 (or AAK62347) by Ralston et al .
  • Group 24 had 98.8% identity to GI:14423318 (or AAK62342) by Ralston et al.
  • Table IV Amino Acid Sequence Identity Groups of Regions between conserveed Domains of Nicotiana p450 Genes D208-AD9 (SEQ. ID. No. 224); D120-AH4 (SEQ. ID. No.
  • D205-BG9 SEQ. ID. No. 202
  • D205-AH4 SEQ. ID. No. 294
  • D259-AB9 SEQ. ID. No. 260
  • D257-AE4 SEQ. ID. No. 268
  • D147-AD3 SEQ. ID. No. 194
  • D249-AE8 SEQ. ID. No. 256
  • D-248-AA6 SEQ. ID. No. 254
  • D233-AG7 SEQ. ID. No. 266; D224-BD11 (SEQ. ID. No. 240)
  • DAF10 D105-AD6 SEQ. ID. No. 172
  • D215-AB5 SEQ. ID. No.
  • D135-AE1 SEQ. ID. No. 190
  • D87A-AF3 SEQ. ID. No. 216
  • D210-BD4 SEQ. ID. No. 262
  • D89-AB1 SEQ. ID. No. 150
  • D89-AD2 SEQ. ID. No. 152
  • 163-AG11 SEQ. ID. No. 198
  • 163-AF12 SEQ. ID. No. 196
  • D267-AF10 SEQ. ID. No. 296
  • D96-AC2 SEQ. ID. No. 160
  • D96-AB6 SEQ. ID. No. 158
  • D207-AA5 SEQ. ID. No. 204
  • D207-AB4 SEQ. ID. No.
  • D207-AC4 SEQ. ID. No. 208
  • D98-AG1 SEQ. ID. No. 164
  • D98-AA1 SEQ. ID. No. 162
  • D209-AA12 SEQ. ID. No. 212
  • D209-AA11 D209-AH10
  • D228-AH8 SEQ. ID. No. 244
  • D228-AD7 SEQ. ID. No. 241
  • D250-AC11 SEQ. ID. No. 258
  • D247-AH1 SEQ. ID. No. 252
  • D284-AH5 (SEQ. ID. No. 298); D110-AF12 (SEQ. ID. No. 176)
  • EXAMPLE 12 NICOTIANA CYTOCHROME P450 CLONES LACKING ONE OR MORE OF THE TOBACCO CYTOCHROME P450 SPECIFIC DOMAINS
  • EXAMPLE 13 USE OF NICOTIANA CYTOCHROME P450 FRAGMENTS AND CLONES IN ALTERED REGULARTION OF TOBACCO PROPERTIES
  • Transgenic tobacco plants are generated by a variety of transformation systems that incorporate nucleic acid fragments or full length genes, selected from those reported herein, in orientations for either down-regulation, for example anti- sense orientation, or over-expression for example, sense orienation.
  • nucleic acid sequence that encodes the entire or a functional part or amino acide sequence of the full-length genes described in this invention are desired that are effective for increasing the expression of a certain enzyme and thus resulting in phenotypic effect within Nicotiana.
  • Nicotiana lines that are homozygous lines are obtained through a series of backcrossing and assessed for phenotypic changes including, but not limited to, analysis of endogenous p450 RNA, transcripts, p450 expressed peptides and concentrations of plant metabolites using techniques commonly avaiable to one having ordinary skill in the art.
  • the changes exhibited in the tobacco plans provide information on the functional role of the selected gene of interest or are of a utility as a preffered Nicotiana plant species .

Abstract

La présente invention a trait à des enzymes p450 et des séquences d'acides nucléiques codant pour des enzymes p450 chez les plantes Nicotiana, et des procédés d'utilisation de ces enzymes et ces séquences d'acides nucléiques pour modifier des phénotypes des végétaux.
EP03809043A 2002-10-16 2003-10-16 Clonage de genes de cytochrome p450 derives de plantes nicotiana Withdrawn EP1581633A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10000366A EP2204444A1 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana
EP11000745A EP2336305A3 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41893302P 2002-10-16 2002-10-16
US418933P 2002-10-16
US48536803P 2003-07-08 2003-07-08
US485368P 2003-07-08
US50398903P 2003-09-18 2003-09-18
US503989P 2003-09-18
PCT/US2003/032722 WO2004035745A2 (fr) 2002-10-16 2003-10-16 Clonage de genes de cytochrome p450 derives de plantes nicotiana

Publications (2)

Publication Number Publication Date
EP1581633A2 EP1581633A2 (fr) 2005-10-05
EP1581633A4 true EP1581633A4 (fr) 2008-10-15

Family

ID=32110829

Family Applications (3)

Application Number Title Priority Date Filing Date
EP11000745A Withdrawn EP2336305A3 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana
EP03809043A Withdrawn EP1581633A4 (fr) 2002-10-16 2003-10-16 Clonage de genes de cytochrome p450 derives de plantes nicotiana
EP10000366A Ceased EP2204444A1 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11000745A Withdrawn EP2336305A3 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10000366A Ceased EP2204444A1 (fr) 2002-10-16 2003-10-16 Clonage de gènes de cytochrome P450 à partir de Nicotiana

Country Status (9)

Country Link
EP (3) EP2336305A3 (fr)
JP (2) JP2006519590A (fr)
KR (1) KR20050052541A (fr)
AP (1) AP2005003286A0 (fr)
AU (1) AU2003301431A1 (fr)
BR (1) BR0315388A (fr)
CA (1) CA2501631A1 (fr)
MX (1) MXPA05004016A (fr)
WO (1) WO2004035745A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855318B2 (en) 2001-11-13 2010-12-21 U.S. Smokeless Tobacco Company Cloning of cytochrome P450 genes from Nicotiana
US8592663B2 (en) 2001-11-13 2013-11-26 U.S. Smokeless Tobacco Company Llc Tobacco nicotine demethylase genomic clone and uses thereof
US7812227B2 (en) 2001-11-13 2010-10-12 U.S. Smokeless Tobacco Company Cloning of cytochrome p450 genes from nicotiana
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US7700834B2 (en) 2001-11-13 2010-04-20 U.S. Smokless Tobacco Company Nicotiana nucleic acid molecules and uses thereof
US10266836B2 (en) 2001-11-13 2019-04-23 U.S. Smokeless Tobacco Company Llc Tobacco nicotine demethylase genomic clone and uses thereof
WO2005038033A2 (fr) * 2003-10-16 2005-04-28 U.S. Smokeless Tobacco Company Clonage des genes cytochromes p450 a partir de nicotiana
CA2477452A1 (fr) * 2002-03-12 2003-09-25 U.S. Smokeless Tobacco Company Clonage des genes du cytochrome p450 a partir de nicotiana
EP1694832B1 (fr) * 2003-10-16 2012-04-18 U.S. Smokeless Tobacco Company LLC Utilisation d'un gene de cytochrome p450 de nicotiana
ES2384243T3 (es) * 2003-10-16 2012-07-02 U.S. Smokeless Tobacco Company Uso de un gen para el citocromo P450 de nicotiana
CN1926235B (zh) * 2003-10-16 2012-07-18 美国无烟烟草有限责任公司 从烟草克隆细胞色素p450基因
ATE525463T1 (de) * 2004-04-29 2011-10-15 Us Smokeless Tobacco Co Genomisches tabaknikotindemethylaseklon und verwendung
JP4753937B2 (ja) * 2004-04-29 2011-08-24 ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー Ｎｉｃｏｔｉａｎａ核酸分子およびその用途
AU2005243214B2 (en) * 2004-04-29 2011-07-07 U.S. Smokeless Tobacco Company Llc Nicotiana nucleic acid molecules and uses thereof
JP5106103B2 (ja) * 2004-04-29 2012-12-26 ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー タバコニコチンデメチラーゼゲノムクローンおよびその用途
CN101384710B (zh) * 2004-04-29 2012-05-02 美国无烟烟草有限责任公司 烟草烟碱脱甲基酶基因组克隆及其应用
ES2535643T3 (es) * 2004-04-29 2015-05-13 U.S. Smokeless Tobacco Company Llc Moléculas de ácido nucleico de nicotiana y usos de las mismas
US8586837B2 (en) 2004-04-29 2013-11-19 U.S. Smokeless Tobacco Company Llc Nicotiana nucleic acid molecules and uses thereof
US20070199097A1 (en) * 2004-09-03 2007-08-23 U.S. Smokeless Tobacco Company Tobacco plants having a mutation in a nicotine demethylase gene
US20060156430A1 (en) * 2005-01-13 2006-07-13 Mcgonigle Brian Novel cytochrome P450 monooxygenase
EP1851317B1 (fr) 2005-02-23 2011-10-26 North Carolina State University Alteration de la teneur en alcaloide de tabac par modification des genes cytochrome p450 specifiques
US8362328B2 (en) 2005-10-07 2013-01-29 Nestec, S.A. Polynucleotides encoding phenylpropanoid pathway enzymes in coffee
WO2008070274A2 (fr) * 2006-10-13 2008-06-12 North Carolina State University Modification de la teneur en alcaloïde du tabac par modification de gènes de cytochrome p450 spécifique
US8319011B2 (en) 2006-12-15 2012-11-27 U.S. Smokeless Tobacco Company Llc Tobacco plants having reduced nicotine demethylase activity
US11332753B2 (en) 2006-12-15 2022-05-17 U.S. Smokeless Tobacco Company Llc Tobacco plants having reduced nicotine demethylase activity
JP2010136624A (ja) * 2007-03-28 2010-06-24 Japan Tobacco Inc 燃焼煙中のカルボニル類含量が低減されたタバコ属植物及びその作製法
EP2220231B1 (fr) 2007-11-12 2017-10-11 North Carolina State University Réduction de la teneur du tabac en alcaloïdes par modification de gènes spécifiques du cytochrome p450
WO2011088180A1 (fr) 2010-01-15 2011-07-21 North Carolina State University Compositions et procédés pour réduire au minimum la synthèse de nornicotine dans le tabac
KR20140034160A (ko) 2011-02-28 2014-03-19 알트리아 클라이언트 서비시스 인코포레이티드 담배 근친교배 식물체 albex1f 및 albex1ms
RU2013139871A (ru) 2011-02-28 2015-04-10 Норт Каролина Стейт Юниверсити Инбредные растения табака ncbex1f, ncbex1mc и nc ex90
US9603335B2 (en) 2013-01-11 2017-03-28 North Carolina State University Tobacco inbred plants K326 SRC, CMS K326 SRC, K346 SRC, CMS K346 SRC, NC1562-1 SRC, NCTG-61 SRC, CMS NCTG-61 SRC and hybrid NC196 SRC
EP2964016A1 (fr) 2013-03-05 2016-01-13 North Carolina State University Plantes autogames et hybrides de tabac et leurs utilisations
CN103718957B (zh) * 2013-12-12 2016-03-02 湖北省烟草科研所 通过未受精胚珠培养雄性不育烟草单倍体的方法
EP3113604A1 (fr) 2014-03-03 2017-01-11 North Carolina State University Plantes hybrides et autogames de tabac et produits de tabac fabriqués à partir de celles-ci
EP3113602A1 (fr) 2014-03-03 2017-01-11 North Carolina State University Plants de tabac autogames et hybrides et produits de tabac obtenus à partir de ceux-ci
EP3113603A1 (fr) 2014-03-03 2017-01-11 North Carolina State University Plantes de tabac autogames et hybrides et produits de tabac fabriqués à partir de celles-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019493A2 (fr) * 1997-10-10 1999-04-22 North Carolina State University Produits de recombinaison cytochrome p-450 et procedes de production de plantes transgeniques resistantes aux herbicides
WO2001034780A2 (fr) * 1999-11-12 2001-05-17 Washington State University Research Foundation Oxygenases de cytochrome p450 et leurs utilisations
WO2002072758A2 (fr) * 2001-03-09 2002-09-19 University Of Kentucky Research Foundation Cytochromes p450 et leurs utilisations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762785A (en) 1982-08-12 1988-08-09 Calgene, Inc. Novel method and compositions for introducting alien DNA in vivo
EP0116718B2 (fr) 1983-01-13 1996-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour l'introduction de gènes exprimables dans les génomes de cellules de plantes et souches d'agrobactérium contenant des vecteurs plasmidiques Ti-hybrides utilisables dans ce procédé
JPS60500438A (ja) 1983-01-17 1985-04-04 モンサント　カンパニ− 植物細胞を形質転換するためのプラスミド
NL8300699A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; werkwijze voor het produceren van agrobacterium tumefaciens bacterien; stabiele cointegraat plasmiden; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
NL8401048A (nl) 1984-04-03 1985-11-01 Rijksuniversiteit Leiden En Pr Werkwijze voor het inbouwen van vreemd dna in het genoom van eenzaadlobbige planten.
US5231019A (en) 1984-05-11 1993-07-27 Ciba-Geigy Corporation Transformation of hereditary material of plants
US5149645A (en) 1984-06-04 1992-09-22 Rijksuniversiteit Leiden Process for introducing foreign DNA into the genome of plants
NL8401780A (nl) 1984-06-04 1986-01-02 Rijksuniversiteit Leiden En Pr Werkwijze voor het inbouwen van vreemd dna in het genoom van planten.
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1987006614A1 (fr) 1986-04-30 1987-11-05 Boyce Thompson Institute For Plant Research, Inc. Transformation de l'adn de cellules vegetales et d'organelles a l'aide d'un champ electrique
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
US5177010A (en) 1986-06-30 1993-01-05 University Of Toledo Process for transforming corn and the products thereof
EP0267159A3 (fr) 1986-11-07 1990-05-02 Ciba-Geigy Ag Procédé de modification génétique de monocotylédones
SE455438B (sv) 1986-11-24 1988-07-11 Aga Ab Sett att senka en brennares flamtemperatur samt brennare med munstycken for oxygen resp brensle
US5004863B2 (en) 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
EP0846771A1 (fr) 1987-05-20 1998-06-10 Novartis AG Plantes de zea mays et plantes transgéniques de zea mays régénérées de protoplastes ou de cellules dérivées de protoplastes
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5141131A (en) 1989-06-30 1992-08-25 Dowelanco Method and apparatus for the acceleration of a propellable matter
EP0558676B1 (fr) 1990-11-23 2000-04-19 Plant Genetic Systems, N.V. Procede de transformation des plantes monocotyledones
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
ES2166361T3 (es) 1992-02-19 2002-04-16 State Of Oregon Acting By & Th Produccion de plantas resistentes a los virus a traves de la introduccion de rna viral intraducible de sentido positivo.
US5679558A (en) 1992-04-15 1997-10-21 Plant Genetic Systems, N.V. Transformation of monocot cells
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5469976A (en) 1993-04-30 1995-11-28 Burchell; James R. Shelf allocation and management system
EP0627752B1 (fr) 1993-06-04 1997-07-23 CAVIS S.r.l. Dispositif à inertie pour l'interruption de la batterie d'une voiture à moteur à combustion interne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019493A2 (fr) * 1997-10-10 1999-04-22 North Carolina State University Produits de recombinaison cytochrome p-450 et procedes de production de plantes transgeniques resistantes aux herbicides
WO2001034780A2 (fr) * 1999-11-12 2001-05-17 Washington State University Research Foundation Oxygenases de cytochrome p450 et leurs utilisations
WO2002072758A2 (fr) * 2001-03-09 2002-09-19 University Of Kentucky Research Foundation Cytochromes p450 et leurs utilisations

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHAPPLE CLINT: "Molecular-genetic analysis of plant cytochrome P450-dependent monooxygenases", ANNUAL REVIEW OF PLANT PHYSIOLOGY AND PLANT MOLECULAR BIOLOGY, ANNUAL REVIEWS INC, XX, 1 January 1998 (1998-01-01), pages 311 - 343, XP002479155, ISSN: 1040-2519 *
DATABASE EMBL [online] 12 May 1998 (1998-05-12), "Eschscholzia californica (S)-N-methylcoclaurine 3'-hydroxylase (CYP82B1) mRNA, complete cds.", XP002493592, retrieved from EBI accession no. EMBL:AF014802 Database accession no. AF014802 *
DATABASE EMBL [online] 16 June 2001 (2001-06-16), "Nicotiana tabacum elicitor-inducible cytochrome P450 (CYP82E1) mRNA, complete cds.", XP002493593, retrieved from EBI accession no. EMBL:AF368381 Database accession no. AF368381 *
DATABASE EMBL [online] 16 June 2001 (2001-06-16), "Nicotiana tabacum elicitor-inducible cytochrome P450 (CYP92A5) mRNA, complete cds.", XP002493596, retrieved from EBI accession no. EMBL:AF368380 Database accession no. AF368380 *
DATABASE EMBL [online] 8 January 1998 (1998-01-08), "Glycine max mRNA for cytochrome P450-like protein, clone CP6", XP002493594, retrieved from EBI accession no. EMBL:Y10982 Database accession no. Y10982 *
HAO DONG-YUN ET AL: "Nicotine N-demethylase in cell-free preparations from tobacco cell cultures", PHYTOCHEMISTRY (OXFORD), vol. 42, no. 2, 1996, pages 325 - 329, XP002493569, ISSN: 0031-9422 *
PAULI H H ET AL: "MOLECULAR CLONING AND FUNCTIONAL HETEROLOGOUS EXPRESSION OF TWO ALLELES ENCODING (S)-N-METHYLCOCLAURINE 3'-HYDROXYLASE (CYP80B1), ANEW METHYL JASMONATE-INDUCIBLE CYTOCHROME P-450-DEPENDENT MONO-OXYGENASE OF BENZYLISOQUINOLINE ALKALOID BIOSYNTHESIS", PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 13, no. 6, 1 January 1998 (1998-01-01), pages 793 - 801, XP000992757, ISSN: 0960-7412 *
RALSTON L ET AL: "Cloning, heterologous expression and functional characterizatin of 5-epi-aristolochene-1,3-dihydroxylase from tobacco (nicotiana tabacum)", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, vol. 393, no. 2, 15 September 2001 (2001-09-15), pages 222 - 235, XP002959517, ISSN: 0003-9861 *
SCHOPFER C R ET AL: "Identification of elicitor-induced cytochrome P450s of soybean Glycine max L.) using differential display of mRNA", MOLECULAR AND GENERAL GENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 258, no. 4, 1 May 1998 (1998-05-01), pages 315 - 322, XP002100399, ISSN: 0026-8925 *
SIMINSZKY BALAZS ET AL: "Conversion of nicotine to nornicotine in Nicotiana tabacum is mediated by CYP82E4, a cytochrome P450 monooxygenase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 102, no. 41, 11 October 2005 (2005-10-11), pages 14919 - 14924, XP002478568, ISSN: 0027-8424 *
TAKEMOTO DAIGO ET AL: "Molecular cloning of a defense-response-related cytochrome P450 gene from tobacco", PLANT AND CELL PHYSIOLOGY, vol. 40, no. 12, December 1999 (1999-12-01), pages 1232 - 1242, XP002493554, ISSN: 0032-0781 *
XU DONGMEI ET AL: "Biochemical and molecular characterizations of nicotine demethylase in tobacco", PHYSIOLOGIA PLANTARUM, vol. 129, no. 2, February 2007 (2007-02-01), pages 307 - 319, XP002493570, ISSN: 0031-9317 *

Also Published As

Publication number Publication date
WO2004035745A2 (fr) 2004-04-29
EP2336305A3 (fr) 2011-10-05
EP1581633A2 (fr) 2005-10-05
MXPA05004016A (es) 2006-01-27
JP2010142241A (ja) 2010-07-01
CA2501631A1 (fr) 2004-04-29
EP2336305A2 (fr) 2011-06-22
JP2006519590A (ja) 2006-08-31
AU2003301431A1 (en) 2004-05-04
KR20050052541A (ko) 2005-06-02
AU2003301431A8 (en) 2008-02-28
EP2204444A1 (fr) 2010-07-07
BR0315388A (pt) 2005-08-23
AP2005003286A0 (en) 2005-06-30
WO2004035745A8 (fr) 2007-12-06

Similar Documents

Publication Publication Date Title
US20070292871A1 (en) Method of screening for cytochrome p450s
EP2204444A1 (fr) Clonage de gènes de cytochrome P450 à partir de Nicotiana
AU2010201696B2 (en) Cloning of cytochrome P450 genes from nicotiana
US8188337B2 (en) Cloning of cytochrome p450 genes from Nicotiana
US7855318B2 (en) Cloning of cytochrome P450 genes from Nicotiana
US9464297B2 (en) Cloning of cytochrome P450 genes from nicotiana
US20080076126A1 (en) Cloning of cytochrome p450 genes from nicotiana
WO2003078577A2 (fr) Clonage des genes du cytochrome p450 a partir de nicotiana
US20080182241A1 (en) Identification and use of cytochrome p450 nucleic acid sequences from tobacco
EP1694832B1 (fr) Utilisation d'un gene de cytochrome p450 de nicotiana
JP2010099074A (ja) タバコ属（Ｎｉｃｏｔｉａｎａ）からのチトクロムｐ４５０遺伝子のクローニング

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050429

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A01H 5/00 20060101ALI20071213BHEP

Ipc: C12N 15/82 20060101AFI20071213BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080915

RIC1 Information provided on ipc code assigned before grant

Ipc: A01H 5/00 20060101ALI20080905BHEP

Ipc: C12N 15/82 20060101ALI20080905BHEP

Ipc: C12N 15/53 20060101ALI20080905BHEP

Ipc: C12N 9/02 20060101AFI20080905BHEP

17Q First examination report despatched

Effective date: 20090120

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: U.S. SMOKELESS TOBACCO COMPANY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100118